Estudo randomizado | Desfechos de longo prazo com nivolumabe associado a ipilimumabe ou nivolumabe isolado vs. ipilimumabe em pacientes com melanoma avançado.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma – Journal of Clinical Oncology

Editorial: CheckMate-067: Raising the Bar for the Next Decade in Oncology – Journal of Clinical Oncology

Estudo original: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma